Zentalis
123 employees on LinkedIn · 2 known investors
Find your way into Zentalis
Sign up to see every warm intro you have to Zentalis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Zentalis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Founders & leadership
JE

Julie EastlandChief Executive Officer and DirectorJulie Eastland is Chief Executive Officer and Director of Zentalis, a biopharmaceutical company developing azenosertib and other pipeline assets. With over 25 years of experience in life sciences, she has previously served as CEO of Harpoon Therapeutics through its acquisition by Merck for $680 million and brings deep financial and commercial expertise to drug development and company scaling.
Board
SM
Scott MyersChairperson
Investors · 2
Decheng Capitallisted by Decheng CapitalMenlo Park
How we know: Decheng Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
2 people who came through Zentalis went on to found or lead other companies.
In the news
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | The Manila Timesmanilatimes.net · Aug 2026
Zentalis raises $92.6M for trials, filings and what followsstocktitan.net · Aug 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering | The Manila Timesmanilatimes.net · Aug 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering - August 13, 2026 - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Zentalis do?
- Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
- Who are Zentalis's investors?
- Zentalis's investors include Decheng Capital, Highlight Capital.

